A collaboration between The University of Texas MD Anderson Cancer Center in Houston and the Broad Institute of MIT and Harvard in Cambridge, MA, is tackling rare cancers. The institutions have created a research platform to generate rare cancer models based on patients' tumor samples, which researchers will sequence to reveal the genomics of the diseases and identify potential therapeutic targets.

You do not currently have access to this content.